Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABSI Absci Corporation.

Pre-Mkt 12-23 06:26:52 EST

3.67

+0.29

+8.58%

盘前3.64

-0.03-0.82%

06:09 EST

High3.79	Low3.39	Vol3.57M
Open3.43	D1 Closing3.38	Amplitude11.83%
Mkt Cap551.86M	Tradable Cap466.09M	Total Shares150.37M
T/O13.06M	T/O Rate2.81%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABSI","market":"US","secType":"STK","nameCN":"Absci Corporation.","latestPrice":3.67,"timestamp":1766437200000,"preClose":3.38,"halted":0,"volume":3570916,"hourTrading":{"tag":"盘前","latestPrice":3.64,"preClose":3.67,"latestTime":"06:09 EST","volume":986,"amount":3599.4099592,"timestamp":1766488167152},"delay":0,"floatShares":127000000,"shares":150371531,"eps":-0.896554,"marketStatus":"Pre-Mkt","change":0.29,"latestTime":"12-23 06:26:52 EST","open":3.43,"high":3.785,"low":3.385,"amount":13064810.383552,"amplitude":0.118343,"askPrice":3.76,"askSize":1000,"bidPrice":3.64,"bidSize":1284,"shortable":3,"etf":0,"ttmEps":-0.896554,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766500200000},"marketStatusCode":1,"adr":0,"listingDate":1626926400000,"exchange":"NASDAQ","adjPreClose":3.67,"preHourTrading":{"tag":"盘前","latestPrice":3.64,"preClose":3.67,"latestTime":"06:09 EST","volume":986,"amount":3599.4099592,"timestamp":1766488167152},"postHourTrading":{"tag":"盘后","latestPrice":3.6495,"preClose":3.67,"latestTime":"19:58 EST","volume":40782,"amount":149874.6263,"timestamp":1766451482984},"volumeRatio":0.8330506664635903,"impliedVol":0.9258,"impliedVolPercentile":0.2651},"requestUrl":"/m/hq/s/ABSI","defaultTab":"news","newsList":[{"id":"2590503068","title":"Absci Price Target Maintained With a $7.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503068?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:50","pubTimestamp":1765540200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 06:50 ET (11:50 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABSI","BK4539","BK4121"],"gpt_icon":0},{"id":"2590015515","title":"Absci Unveils AI-Designed Antibody That Stimulates Human Hair Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2590015515","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590015515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458019,"startTime":"0","endTime":"0","summary":"Absci Corporation has unveiled new preclinical data demonstrating that its AI-designed antibody, ABS-201, effectively stimulates hair growth in human ex vivo scalp models. The research shows that ABS-201 targets the prolactin receptor and promotes hair follicle regeneration by restoring the stem cell niche and influencing key growth modulators. The data suggest ABS-201 may reverse follicular miniaturization and drive the transformation from vellus to terminal hair, offering a potential new approach for treating androgenetic alopecia. These findings were presented during Absci's ABS-201 Key Opinion Leader seminar, with the full dataset and detailed results made available in a slide presentation on the company's investor relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbJvgGy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","IE00B64PRP62.GBP","ABSI","BK4585","BK4139","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590516989","title":"Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516989","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516989?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growthex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular mini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203834/0/en/Absci-Reports-New-Human-Ex-Vivo-Data-Demonstrating-That-ABS-201-Stimulates-Hair-Growth-and-Regenerates-Stem-Cell-Niche-to-Potentially-Reverse-Follicle-Miniaturization.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ABSI","BK4121","KOL"],"gpt_icon":0},{"id":"2590632126","title":"Absci Director Frans Van Houten Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632126","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632126?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:04","pubTimestamp":1765314290,"startTime":"0","endTime":"0","summary":"Frans Van Houten, a Director at Absci Corporation, has reported the acquisition of common shares of Absci Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL61xFn3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Absci Director Frans Van Houten Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","ABSI","BK4539"],"gpt_icon":0},{"id":"2588388260","title":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588388260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588388260?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:24","pubTimestamp":1764854658,"startTime":"0","endTime":"0","summary":"BRIEF-Absci Announces First Participants Dosed In Phase 1/2A Headline Trial Dec 4  - Absci Corp ABSI.O:ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1/2A HEADLINE TRIAL OF AI-DESIGNED ANTIBODY ABS-201 FOR ANDROGENETIC ALOPECIAABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2026ABSCI CORP - PHASE 2 DEVELOPMENT OF ABS-201 IN ENDOMETRIOSIS PLANNED FOR Q4 2026Source text: ID:nGNXR58yFurther company coverage: ABSI.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","ABSI","BK4139"],"gpt_icon":0},{"id":"2588884143","title":"Absci Doses First Volunteers in Phase 1/2a Trial of AI-Designed Antibody for Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884143","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884143?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853216,"startTime":"0","endTime":"0","summary":"Absci Corporation has announced the dosing of the first healthy volunteers in its Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor  antibody designed using Absci's generative AI platform. The clinical trial aims to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of ABS-201 for the treatment of androgenetic alopecia. Interim data from this study are anticipated in the second half of 2026. Additionally, Absci plans to pursue endometriosis as a further indication for ABS-201, with Phase 2 clinical development in endometriosis expected to begin in the fourth quarter of 2026. An interim readout from the Phase 2 trial in endometriosis is projected for the second half of 2027. Additional new human ex vivo data supporting the PRLR mechanism of action will be disclosed at a virtual KOL seminar scheduled for December 11.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL367TTr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4539","ABSI","BK4585","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4121","BK4139"],"gpt_icon":0},{"id":"2588884901","title":"Absci Announces First Participants Dosed in Phase 1/2a Headline™ Trial of AI-Designed Antibody Abs-201™ for Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884901?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4121","ABSI","BK4139"],"gpt_icon":0},{"id":"2588844708","title":"Absci Corp: Interim Data Anticipated in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588844708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588844708?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","ABSI","BK4121"],"gpt_icon":0},{"id":"2588188440","title":"Absci Corp - Phase 2 Development of Abs-201 in Endometriosis Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188440?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA2TCN4X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4139","BK4539","ABSI"],"gpt_icon":0},{"id":"2588056701","title":"Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056701","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056701?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683700,"startTime":"0","endTime":"0","summary":"The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["INTC","NVDS","SGXZ31699556.SGD","2NVD.UK","DNA","RGTI","WOLF","LU0265550359.USD","NVDY","LEU","NVDA","LU1429558221.USD","IONQ","LU2023251221.USD","AI","NVD2.UK","SLI","MP","QBTS","TMQ","MU","SKYT","PPTA","TWST","CEG","NVDX","SNVD.UK","3NVD.UK","ROK","RXRX","TER","NVDL","BWXT","NVIW.SI","TMO","ROIC","LAC","NNE","SDGR","NVD","SMR","ABSI","LU0274383776.USD","NVDD","OKLO","SYM","NVDS.UK","NVDU","NVD3.UK","HON"],"gpt_icon":0},{"id":"2586473958","title":"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbSci (ABSI) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586473958?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:50","pubTimestamp":1764075031,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), AbSci (ABSI ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-absci-absi-and-praxis-precision-medicines-prax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-absci-absi-and-praxis-precision-medicines-prax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","LU2417539215.USD","BK4539","LU0417517546.SGD","HCSG","LU1712237335.SGD","XBI","SG9999015978.USD","SGXZ31699556.SGD","LU2063271972.USD","LU1804176565.USD","BK4137","BK4533","XLV","LABU","LU0079474960.USD","LU1974910355.USD","BK4581","LU1127390331.HKD","SG9999014880.SGD","LU2746668974.SGD","LU2237443549.SGD","PRAX","LU2108987350.USD","LU2211815571.USD","LU1093756325.SGD","LU2361045086.USD","LU0320765992.SGD","LU1917777945.USD","LU2462157665.USD","LU1623119135.USD","LU1023059063.AUD","LU0289739699.SGD","LU2361044949.HKD","LU2237443382.USD","ABSI","BK4139","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU1720051017.SGD","LU1989771016.USD","BK4534","LLY","SG9999014914.USD","LU0882574139.USD","LU0823416689.USD","LU2468319806.SGD","LU0058720904.USD","LU2361044865.SGD","IE0004445239.USD"],"gpt_icon":0},{"id":"1183617548","title":"Stock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1183617548","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183617548?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:35","pubTimestamp":1763044511,"startTime":"0","endTime":"0","summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABSI"],"gpt_icon":0},{"id":"2583566455","title":"Absci Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566455","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583566455?lang=en_us&edition=fundamental","pubTime":"2025-11-13 18:57","pubTimestamp":1763031420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 05:57 ET (10:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABSI","BK4139","BK4539"],"gpt_icon":0},{"id":"1156773280","title":"Stock Track | Absci Corporation Plummets 11.76% in Pre-market Following Disappointing Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1156773280","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156773280?lang=en_us&edition=fundamental","pubTime":"2025-11-13 17:38","pubTimestamp":1763026701,"startTime":"0","endTime":"0","summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plunge 11.76% in pre-market trading on Thursday, extending its losses following a 9.71% decline in the previous regular trading session. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABSI"],"gpt_icon":0},{"id":"1135959188","title":"Stock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1135959188","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135959188?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:03","pubTimestamp":1762995816,"startTime":"0","endTime":"0","summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABSI"],"gpt_icon":0},{"id":"1119470257","title":"Stock Track | Absci Shares Plunge 16.77% After-Hours on Q3 Revenue Miss and Wider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1119470257","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119470257?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:33","pubTimestamp":1762983191,"startTime":"0","endTime":"0","summary":"Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts'...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABSI"],"gpt_icon":0},{"id":"1145586936","title":"Stock Track | Absci Plunges 16.77% After-Hours on Q3 Revenue Miss and Wider-Than-Expected Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1145586936","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145586936?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:33","pubTimestamp":1762983185,"startTime":"0","endTime":"0","summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABSI"],"gpt_icon":0},{"id":"2583958597","title":"Absci reports Q3 EPS (20c), consensus (21c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583958597","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583958597?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:31","pubTimestamp":1762983073,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $378k, consensus $1.58M. “This quarter marks a pivotal inflection point for Absci (ABSI) as we sharpen our focus on ABS-201, adv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/absci-reports-q3-eps-20c-consensus-21c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/absci-reports-q3-eps-20c-consensus-21c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABSI","BK4539","BK4139","BK4121"],"gpt_icon":0},{"id":"2583583655","title":"Absci Corporation Showcases AI-Powered Antibody Design and Pipeline Progress in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583655","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583655?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:19","pubTimestamp":1762982381,"startTime":"0","endTime":"0","summary":"Absci Corporation has released a corporate presentation detailing advancements in its AI-driven platform for antibody and biologic drug discovery. The presentation highlights the company's integrated approach, combining proprietary high-throughput screening assays with advanced generative AI models to enable _de novo_ antibody design and lead optimization. Absci describes a continuous six-week \"lab in the loop\" cycle, where AI-generated candidates are validated in a 77,000 square foot laboratory, enhancing model performance over time. The pipeline overview includes updates on ABS-201, an anti-prolactin receptor antibody program advancing to Phase 1/2a clinical trials for androgenetic alopecia and an anticipated Phase 2 trial for endometriosis. ABS-101, an anti-TL1A antibody, has reported Phase 1 interim results demonstrating an extended half-life compared to first-generation competitors, with partnership discussions underway. Early-stage programs in oncology and immunology are also in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL92XsmV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4121","BK4139","BK4539"],"gpt_icon":0},{"id":"2583915588","title":"Absci reports Q3 revenue of $0.4 million and net loss of $28.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583915588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583915588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:07","pubTimestamp":1762981636,"startTime":"0","endTime":"0","summary":"Absci Corporation reported revenue of $0.4 million for the third quarter ended September 30, 2025, down from $1.7 million in the same period in 2024. Research and development expenses increased to $19.2 million from $18.0 million, primarily due to the advancement of internal programs. Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million, mainly due to lower personnel-related costs. Net loss for the quarter was $28.7 million, compared to $27.4 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million as of June 30, 2025. The company reported interim Phase 1 results for ABS-101  and is on track to initiate a Phase 1/2a trial for ABS-201  in December. Absci is also expanding the ABS-201 strategy to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7LYS1q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","BK4139","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","BK4121","ABSI","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.absci.com","stockEarnings":[{"period":"1week","weight":0.0826},{"period":"1month","weight":0.2526},{"period":"3month","weight":0.4115},{"period":"6month","weight":0.3297},{"period":"1year","weight":0.2274},{"period":"ytd","weight":0.4008}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.168714},{"month":2,"riseRate":0.75,"avgChangeRate":0.10205},{"month":3,"riseRate":0.25,"avgChangeRate":-0.130531},{"month":4,"riseRate":0.25,"avgChangeRate":-0.121758},{"month":5,"riseRate":0.25,"avgChangeRate":-0.047908},{"month":6,"riseRate":0,"avgChangeRate":-0.147252},{"month":7,"riseRate":0.75,"avgChangeRate":0.242017},{"month":8,"riseRate":0.2,"avgChangeRate":-0.131623},{"month":9,"riseRate":0.2,"avgChangeRate":-0.114873},{"month":10,"riseRate":0.8,"avgChangeRate":0.133791},{"month":11,"riseRate":0.2,"avgChangeRate":-0.134033},{"month":12,"riseRate":0.4,"avgChangeRate":0.229793}],"exchange":"NASDAQ","name":"Absci Corporation.","nameEN":"Absci Corporation."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Absci Corporation.,ABSI,Absci Corporation.股票,Absci Corporation.股票老虎,Absci Corporation.股票老虎国际,Absci Corporation.行情,Absci Corporation.股票行情,Absci Corporation.股价,Absci Corporation.股市,Absci Corporation.股票价格,Absci Corporation.股票交易,Absci Corporation.股票购买,Absci Corporation.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}